Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
Item | Description | The company |
---|---|---|
EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Medtronic PLC EBITDA increased from 2021 to 2022 but then slightly decreased from 2022 to 2023. |
Enterprise Value to EBITDA Ratio, Current
Selected Financial Data (US$ in millions) | |
Enterprise value (EV) | 123,317) |
Earnings before interest, tax, depreciation and amortization (EBITDA) | 8,697) |
Valuation Ratio | |
EV/EBITDA | 14.18 |
Benchmarks | |
EV/EBITDA, Competitors1 | |
Abbott Laboratories | 18.31 |
Cigna Group | 12.58 |
CVS Health Corp. | 7.45 |
Elevance Health Inc. | 10.76 |
Humana Inc. | 6.10 |
Intuitive Surgical Inc. | 53.72 |
Shockwave Medical Inc. | 62.86 |
UnitedHealth Group Inc. | 13.32 |
EV/EBITDA, Sector | |
Health Care Equipment & Services | 13.23 |
EV/EBITDA, Industry | |
Health Care | 18.29 |
Based on: 10-K (reporting date: 2023-04-28).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 | Apr 27, 2018 | ||
---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||
Enterprise value (EV)1 | 132,878) | 131,529) | 183,640) | 139,945) | 148,881) | 131,974) | |
Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 8,697) | 8,777) | 7,522) | 7,810) | 9,300) | 9,465) | |
Valuation Ratio | |||||||
EV/EBITDA3 | 15.28 | 14.99 | 24.41 | 17.92 | 16.01 | 13.94 | |
Benchmarks | |||||||
EV/EBITDA, Competitors4 | |||||||
Abbott Laboratories | 19.49 | 15.85 | 17.42 | 25.99 | 21.70 | — | |
Cigna Group | 12.11 | 8.88 | 9.06 | 6.31 | 8.42 | — | |
CVS Health Corp. | 8.03 | 12.42 | 10.41 | 8.56 | 9.43 | — | |
Elevance Health Inc. | 10.24 | 10.26 | 10.05 | 7.57 | 9.05 | — | |
Humana Inc. | 7.33 | 11.59 | 11.22 | 6.91 | 9.30 | — | |
Intuitive Surgical Inc. | 53.82 | 41.52 | 44.54 | 59.12 | 37.53 | — | |
Shockwave Medical Inc. | 49.39 | 52.02 | — | — | — | — | |
UnitedHealth Group Inc. | 13.60 | 15.11 | 17.39 | 13.39 | 13.82 | — | |
EV/EBITDA, Sector | |||||||
Health Care Equipment & Services | 13.58 | 13.91 | 15.27 | 12.79 | 12.97 | — | |
EV/EBITDA, Industry | |||||||
Health Care | 18.80 | 13.80 | 13.98 | 16.48 | 14.28 | — |
Based on: 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24), 10-K (reporting date: 2019-04-26), 10-K (reporting date: 2018-04-27).
3 2023 Calculation
EV/EBITDA = EV ÷ EBITDA
= 132,878 ÷ 8,697 = 15.28
4 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
EV/EBITDA | Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. | Medtronic PLC EV/EBITDA ratio decreased from 2021 to 2022 but then slightly increased from 2022 to 2023. |